FH and neoplasm: In the case of localized radio-FH therapy of a solid tumor where radio-FH can be directly injected in the tumor site, the FH NPs can be radiolabeled with both a long range beta emitter (for sufficient dose spatial coverage) and a short range alpha emitter (to enhance the biological effective dose) to optimize therapeutic efficacy.